NLRP3 Inflammasome May Be a Biomarker for Risk Stratification in Patients with Acute Coronary Syndrome

• Published in: Journal of inflammation research 2022-01, Vol.15, p.6595-6605
• Main Authors: Mo, De-Gang, Wang, Lin, Han, Qian-Feng, Yu, Kang, Liu, Jia-Hui, Yao, Heng-Chen
• Format: Article
• Language: English
• Subjects: acute coronary syndrome; Acute coronary syndromes; Age; biomarker; Biomarkers; Blood; Cardiovascular disease; Care and treatment; Clopidogrel; Coronary heart disease; Coronary vessels; Correlation analysis; Diabetes; Health aspects; Heart attacks; Hospitals; Hypertension; Inflammasomes; Laboratories; Medical imaging; Medical prognosis; Medical research; Medicine, Experimental; Myocardial infarction; nlrp3 inflammasome; Normal distribution; Original Research; Patients; Plasma; Proteins; Regression analysis; risk stratification; Statistical analysis; Thrombolysis; thrombolysis in myocardial infarction risk score for secondary prevention; trs-2p; Type 2 diabetes
• ISSN: 1178-7031; 1178-7031
• DOI: 10.2147/JIR.S383903

Acute coronary syndrome (ACS) has a high incidence and mortality rate worldwide, which has a considerable negative impact on the global economy. This study aimed to identify a group of ACS patients at a high risk of recurrent adverse cardiac events using the plasma NLRP3 inflammasome. ACS patients admitted to Liaocheng People's Hospital between June 2021 and March 2022 were enrolled in this study. Patients were divided into low (levels < 3.84 ng/mL) and high (levels ≥ 3.84 ng/mL) groups based on the median NLRP3 inflammasome levels. The patients were divided into three groups according to the Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention (TRS-2P): low (scores ≤ 2 points), intermediate (scores = 3 points), and high (score ≥ 4 points) risk. We investigated the relationship between NLRP3 inflammasome and laboratory indicators. Additionally, we examined whether the NLRP3 inflammasome was an independent predictor of high TRS-2P and explored the applicability of the plasma NLRP3 inflammasome for predicting high TRS-2P. Logistic regression analysis revealed that NLRP3 inflammasome was an independent predictor of high TRS-2P (odds ratio [OR]:2.013; 95% confidence interval [CI]: 1.174-3.452). The area under the receiver operating characteristic curve value of the NLRP3 inflammasome was 0.674 (95% CI: 0.611-0.737; P < 0.001). NLRP3 inflammasome levels are an independent predictive factor for high TRS-2P levels, which indicates that the NLRP3 inflammasome may help predict the prognosis of ACS patients.